{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:39:36Z","timestamp":1784547576945,"version":"3.55.0"},"reference-count":60,"publisher":"e-Century Publishing Corporation","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/qdxj3369","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T05:45:34Z","timestamp":1725515134000},"page":"4163-4173","source":"Crossref","is-referenced-by-count":2,"title":["Effects of Bushen Huayu Decoction combined with entecavir on liver function and hepatic fibrosis in patients with compensated cirrhosis"],"prefix":"10.62347","volume":"16","author":[{"given":"Wei","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Kim MN, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Jang SY, Tak WY, Kweon YO, Park SY and Kim SU. ALT is not associated with achieving subcirrhotic liver stiffness and HCC during entecavir therapy in HBV-related cirrhosis. Clin Gastroenterol Hepatol 2023; 21: 2278-2287, e5.","DOI":"10.1016\/j.cgh.2022.10.035"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.21037\/atm-22-5010","article-title":"Diagnostic significance of serum type IV collagen (IVC) combined with aspartate aminotransferase (AST)\/alanine aminotransferase (ALT) ratio in liver fibrosis","volume":"10","author":"Niu","year":"2022","unstructured":"Niu A and Qi T. Diagnostic significance of serum type IV collagen (IVC) combined with aspartate aminotransferase (AST)\/alanine aminotransferase (ALT) ratio in liver fibrosis. Ann Transl Med 2022; 10: 1310.","journal-title":"Ann Transl Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"599","DOI":"10.5009\/gnl20171","article-title":"Direct bilirubin is more valuable than total bilirubin for predicting prognosis in patients with liver cirrhosis","volume":"15","author":"Lee","year":"2021","unstructured":"Lee HA, Jung JY, Lee YS, Jung YK, Kim JH, An H, Yim HJ, Jeen YT, Yeon JE, Byun KS, Um SH and Seo YS. Direct bilirubin is more valuable than total bilirubin for predicting prognosis in patients with liver cirrhosis. Gut Liver 2021; 15: 599-605.","journal-title":"Gut Liver"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"6305","DOI":"10.1021\/acsnano.0c02633","article-title":"Liver-targeted siRNA lipid nanoparticles treat hepatic cirrhosis by dual antifibrotic and anti-inflammatory activities","volume":"14","author":"Zhang","year":"2020","unstructured":"Zhang J, Shen H, Xu J, Liu L, Tan J, Li M, Xu N, Luo S, Wang J, Yang F, Tang J, Li Q, Wang Y, Yu L and Yan Z. Liver-targeted siRNA lipid nanoparticles treat hepatic cirrhosis by dual antifibrotic and anti-inflammatory activities. ACS Nano 2020; 14: 6305-6322.","journal-title":"ACS Nano"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jhep.2022.03.009","article-title":"Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death","volume":"77","author":"Zanetto","year":"2022","unstructured":"Zanetto A, Campello E, Bulato C, Gavasso S, Farinati F, Russo FP, Tormene D, Burra P, Senzolo M and Simioni P. Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death. J Hepatol 2022; 77: 660-669.","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.3390\/cells11142221","article-title":"Role of hepatocyte senescence in the activation of hepatic stellate cells and liver fibrosis progression","volume":"11","author":"Wijayasiri","year":"2022","unstructured":"Wijayasiri P, Astbury S, Kaye P, Oakley F, Alexander GJ, Kendall TJ and Aravinthan AD. Role of hepatocyte senescence in the activation of hepatic stellate cells and liver fibrosis progression. Cells 2022; 11: 2221.","journal-title":"Cells"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s00535-023-01963-2","article-title":"Shortterm hepatocyte function and portal hypertension outcomes of sofosbuvir\/velpatasvir for decompensated hepatitis C-related cirrhosis","volume":"58","author":"Kotani","year":"2023","unstructured":"Kotani K, Enomoto M, Uchida-Kobayashi S, Tamori A, Yukawa-Muto Y, Odagiri N, Motoyama H, Kozuka R, Kawamura E, Hagihara A, Fujii H, Kageyama K, Yamamoto A, Yoshida A, Higashiyama S, Kawabe J and Kawada N. Shortterm hepatocyte function and portal hypertension outcomes of sofosbuvir\/velpatasvir for decompensated hepatitis C-related cirrhosis. J Gastroenterol 2023; 58: 394-404.","journal-title":"J Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12876-023-02877-2","article-title":"Serum liver fibrosis markers predict hepatic decompensation in compensated cirrhosis","volume":"23","author":"Chen","year":"2023","unstructured":"Chen Q, Mei L, Zhong R, Han P, Wen J, Han X, Zhai L, Zhao L and Li J. Serum liver fibrosis markers predict hepatic decompensation in compensated cirrhosis. BMC Gastroenterol 2023; 23: 317.","journal-title":"BMC Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/hep.30175","article-title":"The utility of MR elastography to differentiate nodular regenerative hyperplasia from cirrhosis","volume":"69","author":"Navin","year":"2019","unstructured":"Navin PJ, Hilscher MB, Welle CL, Mounajjed T, Torbenson MS, Kamath PS and Venkatesh SK. The utility of MR elastography to differentiate nodular regenerative hyperplasia from cirrhosis. Hepatology 2019; 69: 452-454.","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1111\/jgh.15538","article-title":"Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort)","volume":"36","author":"Hsu","year":"2021","unstructured":"Hsu WF, Tsai PC, Chen CY, Tseng KC, Lai HC, Kuo HT, Hung CH, Tung SY, Wang JH, Chen JJ, Lee PL, Chien RN, Lin CY, Yang CC, Lo GH, Tai CM, Lin CW, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Su WW, Chu CH, Chen CJ, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Huang JF, Dai CY, Chuang WL, Yu ML and Peng CY. Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort). J Gastroenterol Hepatol 2021; 36: 2884-2892.","journal-title":"J Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1161\/CIRCULATIONAHA.121.056870","article-title":"Incidence and expected probability of liver cirrhosis and hepatocellular carcinoma after fontan operation","volume":"144","author":"Nii","year":"2021","unstructured":"Nii M, Inuzuka R, Inai K, Shimada E, Shinohara T, Kogiso T, Ono H, Ootsuki S, Kurita Y, Takeda A, Hirono K, Takei K, Yasukochi S, Yoshikawa T, Furutani Y, Shinozaki T, Matsuyama Y, Senzaki H, Tokushige K and Nakanishi T. Incidence and expected probability of liver cirrhosis and hepatocellular carcinoma after fontan operation. Circulation 2021; 144: 2043-2045.","journal-title":"Circulation"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s10147-021-02111-7","article-title":"Novel combined fibrosis-based index predicts the long-term outcomes of hepatocellular carcinoma after hepatic resection","volume":"27","author":"Yanagaki","year":"2022","unstructured":"Yanagaki M, Shirai Y, Hamura R, Taniai T, Tanji Y, Haruki K, Furukawa K, Onda S, Shiba H and Ikegami T. Novel combined fibrosis-based index predicts the long-term outcomes of hepatocellular carcinoma after hepatic resection. Int J Clin Oncol 2022; 27: 717-728.","journal-title":"Int J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"24338","DOI":"10.1002\/jcla.24338","article-title":"Prognostic value of albumin-related ratios in HBV-associated decompensated cirrhosis","volume":"36","author":"Zhang","year":"2022","unstructured":"Zhang T, Ye B and Shen J. Prognostic value of albumin-related ratios in HBV-associated decompensated cirrhosis. J Clin Lab Anal 2022; 36: 24338.","journal-title":"J Clin Lab Anal"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1055\/s-0041-1729973","article-title":"Finite antiviral therapy in chronic hepatitis B patients with cirrhosis","volume":"41","author":"Jeng","year":"2021","unstructured":"Jeng WJ and Liaw YF. Finite antiviral therapy in chronic hepatitis B patients with cirrhosis. Semin Liver Dis 2021; 41: 349-357.","journal-title":"Semin Liver Dis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3892\/etm.2020.9600","article-title":"HBV induces liver fibrosis via the TGF-β1\/miR-21-5p pathway","volume":"21","author":"Li","year":"2021","unstructured":"Li W, Yu X, Chen X, Wang Z, Yin M, Zhao Z and Zhu C. HBV induces liver fibrosis via the TGF-β1\/miR-21-5p pathway. Exp Ther Med 2021; 21: 169.","journal-title":"Exp Ther Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1097\/HEP.0000000000000037","article-title":"Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis","volume":"77","author":"Huang","year":"2023","unstructured":"Huang DQ, Tamaki N, Lee HW, Park SY, Lee YR, Lee HW, Lim SG, Lim TS, Kurosaki M, Marusawa H, Mashiba T, Kondo M, Uchida Y, Kobashi H, Furuta K, Izumi N, Kim BK and Sinn DH. Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis. Hepatology 2023; 77: 1746-1756.","journal-title":"Hepatology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.jhep.2022.07.037","article-title":"Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis","volume":"77","author":"Wang","year":"2022","unstructured":"Wang Q, Zhao H, Deng Y, Zheng H, Xiang H, Nan Y, Hu J, Meng Q, Xu X, Fang J, Xu J, Wang X, You H, Pan CQ, Xie W and Jia J. Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis. J Hepatol 2022; 77: 1564-1572.","journal-title":"J Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/hep.32285","article-title":"Hepatic fibrosis 2022: unmet needs and a blueprint for the future","volume":"75","author":"Friedman","year":"2022","unstructured":"Friedman SL and Pinzani M. Hepatic fibrosis 2022: unmet needs and a blueprint for the future. Hepatology 2022; 75: 473-488.","journal-title":"Hepatology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s11655-023-3735-0","article-title":"Research on mechanisms of Chinese medicines in prevention and treatment of postoperative adhesion","volume":"29","author":"Wang","year":"2023","unstructured":"Wang YL, Zhang HX, Chen YQ, Yang LL, Li ZJ, Zhao M, Li WL, Bian YY and Zeng L. Research on mechanisms of Chinese medicines in prevention and treatment of postoperative adhesion. Chin J Integr Med 2023; 29: 556-565.","journal-title":"Chin J Integr Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/aps.2017.101","article-title":"A metabolic mechanism analysis of Fuzheng-Huayu formula for improving liver cirrhosis with traditional Chinese medicine syndromes","volume":"39","author":"Song","year":"2018","unstructured":"Song YN, Chen J, Cai FF, Lu YY, Chen QL, Zhang YY, Liu P and Su SB. A metabolic mechanism analysis of Fuzheng-Huayu formula for improving liver cirrhosis with traditional Chinese medicine syndromes. Acta Pharmacol Sin 2018; 39: 942-951.","journal-title":"Acta Pharmacol Sin"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1002\/jsfa.10281","article-title":"Bioavailability and prebiotic potential of Carapax Trionycis, a waste from soft-shelled turtle processing","volume":"100","author":"Wang","year":"2020","unstructured":"Wang S, Chen G, Chen K and Kan J. Bioavailability and prebiotic potential of Carapax Trionycis, a waste from soft-shelled turtle processing. J Sci Food Agric 2020; 100: 2554-2567.","journal-title":"J Sci Food Agric"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1002\/jmv.27761","article-title":"Identification of potential plasma markers for hepatitis B virus-related chronic hepatitis and liver fibrosis\/cirrhosis","volume":"94","author":"Zhao","year":"2022","unstructured":"Zhao D, Yu S, Guo P, Zhang X, Tang Y, Dong C, Zhao S, Li L, Al-Dhamin Z, Ai R, Xue N, Dong S and Nan Y. Identification of potential plasma markers for hepatitis B virus-related chronic hepatitis and liver fibrosis\/cirrhosis. J Med Virol 2022; 94: 3900-3910.","journal-title":"J Med Virol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.joim.2020.03.001","article-title":"Guidelines for diagnosis and treatment of hepatic fibrosis with integrated traditional Chinese and Western medicine (2019 edition)","volume":"18","author":"LM","year":"2020","unstructured":"Xu LM and Liu P; Hepatology Committee of Chinese Association of Integrative Medicine, China. Guidelines for diagnosis and treatment of hepatic fibrosis with integrated traditional Chinese and Western medicine (2019 edition). J Integr Med 2020; 18: 203-213.","journal-title":"J Integr Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"482","DOI":"10.26855\/ijcemr.2023.07.032","article-title":"Treatment of renal edema based on TCM syndrome differentiation","volume":"7","author":"YN","year":"2023","unstructured":"Li YN, Cheng XP and Geng MX. Treatment of renal edema based on TCM syndrome differentiation. Int J Clin Exp Med 2023; 7: 482-486.","journal-title":"Int J Clin Exp Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/cid\/ciac823","article-title":"Hepatitis B virus (HBV) replication during tenofovir therapy is frequent in human immunodeficiency virus\/HBV coinfection","volume":"76","author":"Hofmann","year":"2023","unstructured":"Hofmann E, Surial B, Boillat-Blanco N, Günthard HF, Stöckle M, Bernasconi E, Schmid P, Calmy A, Suter-Riniker F, Rauch A, Wandeler G and Béguelin C; Swiss HIV Cohort Study. Hepatitis B virus (HBV) replication during tenofovir therapy is frequent in human immunodeficiency virus\/HBV coinfection. Clin Infect Dis 2023; 76: 730-733.","journal-title":"Clin Infect Dis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"5395","DOI":"10.3748\/wjg.v29.i38.5395","article-title":"Hepatitis D virus dual-infection among Chinese hepatitis B patient related to hepatitis B surface antigen, hepatitis B virus DNA and age","volume":"29","author":"Zi","year":"2023","unstructured":"Zi J, Li YH, Wang XM, Xu HQ, Liu WH, Cui JY, Niu JQ and Chi XM. Hepatitis D virus dual-infection among Chinese hepatitis B patient related to hepatitis B surface antigen, hepatitis B virus DNA and age. World J Gastroenterol 2023; 29: 5395-5405.","journal-title":"World J Gastroenterol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/jvh.13750","article-title":"Safe co-administration of direct-acting antivirals and direct oral anticoagulants among patients with hepatitis C virus infection: an international multicenter retrospective cohort study","volume":"29","author":"McDaniel","year":"2022","unstructured":"McDaniel K, Utz AE, Akbashev M, Fuller KG, Boyle A, Davidson K, Marra F, Shah S, Cartwright EJ, Arora AA, DuPont S and Miller LS. Safe co-administration of direct-acting antivirals and direct oral anticoagulants among patients with hepatitis C virus infection: an international multicenter retrospective cohort study. J Viral Hepat 2022; 29: 1073-1078.","journal-title":"J Viral Hepat"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.arbr.2020.08.015","article-title":"Profibrotic factors as potential biomarkers of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis","volume":"57","author":"Lopez-Lopez L","year":"2021","unstructured":"Lopez-Lopez L, Cabrera Cesar E, Lara E, Hidalgo-San Juan MV, Parrado C, Martín-Montañez E and Garcia-Fernandez M. Profibrotic factors as potential biomarkers of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis. Arch Bronconeumol (Engl Ed) 2021; 57: 231-233.","journal-title":"Arch Bronconeumol (Engl Ed)"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1021\/acs.molpharmaceut.1c00462","article-title":"Non-uniformity of changes in drug-metabolizing enzymes and transporters in liver cirrhosis: implications for drug dosage adjustment","volume":"18","author":"El-Khateeb","year":"2021","unstructured":"El-Khateeb E, Achour B, Al-Majdoub ZM, Barber J and Rostami-Hodjegan A. Non-uniformity of changes in drug-metabolizing enzymes and transporters in liver cirrhosis: implications for drug dosage adjustment. Mol Pharm 2021; 18: 3563-3577.","journal-title":"Mol Pharm"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1097\/hep.0000000000000459","article-title":"Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase","volume":"78","author":"Huang","year":"2023","unstructured":"Huang DQ, Tran A, Yeh ML, Yasuda S, Tsai PC, Huang CF, Dai CY, Ogawa E, Ishigami M, Ito T, Kozuka R, Enomoto M, Suzuki T, Yoshimaru Y, Preda CM, Marin RI, Sandra I, Tran S, Quek SXZ, Khine HHTW, Itokawa N, Atsukawa M, Uojima H, Watanabe T, Takahashi H, Inoue K, Maeda M, Hoang JK, Trinh L, Barnett S, Cheung R, Lim SG, Trinh HN, Chuang WL, Tanaka Y, Toyoda H, Yu ML and Nguyen MH. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase. Hepatology 2023; 78: 1558-1568.","journal-title":"Hepatology"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1007\/s12072-021-10240-4","article-title":"Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis","volume":"15","author":"Wu","year":"2021","unstructured":"Wu X, Hong J, Zhou J, Sun Y, Li L, Xie W, Piao H, Xu X, Jiang W, Feng B, Chen Y, Xu M, Cheng J, Meng T, Wang B, Chen S, Kong Y, Ou X, You H and Jia J. Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis. Hepatol Int 2021; 15: 1318-1327.","journal-title":"Hepatol Int"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Li P, Wang Y, Yu J, Yu J, Tao Q, Zhang J, Lau WY, Zhou W and Huang G. Tenofovir vs entecavir among patients with HBV-related HCC after resection. JAMA Netw Open 2023; 6: e2340353.","DOI":"10.1001\/jamanetworkopen.2023.40353"},{"key":"ref32","unstructured":"Kazmi SS, Naz Awan A, Khan A, Muhammad G, Kanwal A and Haneef M. Molecular dynamics simulation of entecavir-silver nanoparticles at different biological pH. Pak J Pharm Sci 2022; 35: 973-983."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jinf.2021.08.044","article-title":"On-treatment HBV RNA dynamic predicts entecavir-induced HBeAg seroconversion in children with chronic hepatitis B","volume":"83","author":"Wu","year":"2021","unstructured":"Wu Y, Wen J, Tang G, Zhang J and Xin J. On-treatment HBV RNA dynamic predicts entecavir-induced HBeAg seroconversion in children with chronic hepatitis B. J Infect 2021; 83: 594-600.","journal-title":"J Infect"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jhep.2022.10.028","article-title":"Hepatocyte-specific Mas activation enhances lipophagy and fatty acid oxidation to protect against acetaminophen-induced hepatotoxicity in mice","volume":"78","author":"Chen","year":"2023","unstructured":"Chen S, Lu Z, Jia H, Yang B, Liu C, Yang Y, Zhang S, Wang Z, Yang L, Li S, Li J and Yang C. Hepatocyte-specific Mas activation enhances lipophagy and fatty acid oxidation to protect against acetaminophen-induced hepatotoxicity in mice. J Hepatol 2023; 78: 543-557.","journal-title":"J Hepatol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/s41575-022-00711-w","article-title":"Investigating two versus three doses of mRNA vaccine in patients with cirrhosis","volume":"19","author":"Hindson","year":"2022","unstructured":"Hindson J. Investigating two versus three doses of mRNA vaccine in patients with cirrhosis. Nat Rev Gastroenterol Hepatol 2022; 19: 752.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1148\/radiol.211172","article-title":"Sarcopenia in patients with cirrhosis after transjugular intrahepatic portosystemic shunt placement","volume":"303","author":"Liu","year":"2022","unstructured":"Liu J, Ma J, Yang C, Chen M, Shi Q, Zhou C, Huang S, Chen Y, Wang Y, Li T and Xiong B. Sarcopenia in patients with cirrhosis after transjugular intrahepatic portosystemic shunt placement. Radiology 2022; 303: 711-719.","journal-title":"Radiology"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/osp4.484","article-title":"Addition of hyaluronic acid to the FIB-4 liver fibrosis score improves prediction of incident cirrhosis and hepatocellular carcinoma in type 2 diabetes: the edinburgh type 2 diabetes study","volume":"7","author":"Grecian","year":"2021","unstructured":"Grecian SM, McLachlan S, Fallowfield JA, Hayes PC, Guha IN, Morling JR, Glancy S, Williamson RM, Reynolds RM, Frier BM, Zammitt NN, Price JF and Strachan MWJ. Addition of hyaluronic acid to the FIB-4 liver fibrosis score improves prediction of incident cirrhosis and hepatocellular carcinoma in type 2 diabetes: the edinburgh type 2 diabetes study. Obes Sci Pract 2021; 7: 497-508.","journal-title":"Obes Sci Pract"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Aleknaviciute-Valiene G and Banys V. Clinical importance of laboratory biomarkers in liver fibrosis. Biochem Med (Zagreb) 2022; 32: 030501.","DOI":"10.11613\/BM.2022.030501"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/liv.14070","article-title":"Collagen type IV remodelling gender-specifically predicts mortality in decompensated cirrhosis","volume":"39","author":"Lehmann","year":"2019","unstructured":"Lehmann J, Praktiknjo M, Nielsen MJ, Schierwagen R, Meyer C, Thomas D, Violi F, Strassburg CP, Bendtsen F, Møller S, Krag A, Karsdal MA, Leeming DJ and Trebicka J. Collagen type IV remodelling gender-specifically predicts mortality in decompensated cirrhosis. Liver Int 2019; 39: 885-893.","journal-title":"Liver Int"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00423-023-02813-8","article-title":"Evaluation of preoperative procollagen type 1 N-terminal peptide and collagen type 1 C-telopeptide levels in the prediction of postoperative hypocalcemia in patients undergoing parathyroidectomy due to primary hyperparathyroidism","volume":"408","author":"Martl&#x131","year":"2023","unstructured":"Martlı HF, Saylam B, Er S, Yücel Ç and Tez M. Evaluation of preoperative procollagen type 1 N-terminal peptide and collagen type 1 C-telopeptide levels in the prediction of postoperative hypocalcemia in patients undergoing parathyroidectomy due to primary hyperparathyroidism. Langenbecks Arch Surg 2023; 408: 71.","journal-title":"Langenbecks Arch Surg"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"4108","DOI":"10.21037\/apm-20-1623","article-title":"Comparison of four markers of hepatic fibrosis and hepatic function indices in patients with liver cirrhosis and hepatoma","volume":"10","author":"HY","year":"2021","unstructured":"Ma HY, Dong L, Quan SZ, Li RY and Wang XR. Comparison of four markers of hepatic fibrosis and hepatic function indices in patients with liver cirrhosis and hepatoma. Ann Palliat Med 2021; 10: 4108-4121.","journal-title":"Ann Palliat Med"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/jvh.13293","article-title":"Alanine aminotransferase influencing performances of routine available tests detecting hepatitis B-related cirrhosis","volume":"27","author":"Chen","year":"2020","unstructured":"Chen YP, Huang LW, Lin XY, Hu XM, Liang XE and Jiang RL. Alanine aminotransferase influencing performances of routine available tests detecting hepatitis B-related cirrhosis. J Viral Hepat 2020; 27: 826-836.","journal-title":"J Viral Hepat"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2217\/bmm-2020-0691","article-title":"Biomarkers of cholestasis","volume":"15","author":"Pieters","year":"2021","unstructured":"Pieters A, Gijbels E, Cogliati B, Annaert P, Devisscher L and Vinken M. Biomarkers of cholestasis. Biomark Med 2021; 15: 437-454.","journal-title":"Biomark Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"7747","DOI":"10.1021\/acsami.2c19269","article-title":"Albumin-based silibinin nanocrystals targeting activated hepatic stellate cells for liver fibrosis therapy","volume":"15","author":"Luo","year":"2023","unstructured":"Luo S, Yang Y, Zhao T, Zhang R, Fang C, Li Y, Zhang Z and Gong T. Albumin-based silibinin nanocrystals targeting activated hepatic stellate cells for liver fibrosis therapy. ACS Appl Mater Interfaces 2023; 15: 7747-7758.","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"103150","DOI":"10.1016\/j.psj.2023.103150","article-title":"Effects of dietary incorporation of Radix rehmanniae praeparata polysaccharide on growth performance, digestive physiology, blood metabolites, meat quality, and tibia characteristics in broiler chickens","volume":"102","author":"Yang","year":"2023","unstructured":"Yang B, Li X, Badran AMM and Abdel-Moneim AE. Effects of dietary incorporation of Radix rehmanniae praeparata polysaccharide on growth performance, digestive physiology, blood metabolites, meat quality, and tibia characteristics in broiler chickens. Poult Sci 2023; 102: 103150.","journal-title":"Poult Sci"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"11967","DOI":"10.1021\/acs.jafc.2c03851","article-title":"Cornel iridoid glycoside alleviates microglia-mediated inflammatory response via the NLRP3\/calpain pathway","volume":"70","author":"Zheng","year":"2022","unstructured":"Zheng C, Yang C, Gao D, Zhang L, Li Y, Li L and Zhang L. Cornel iridoid glycoside alleviates microglia-mediated inflammatory response via the NLRP3\/calpain pathway. J Agric Food Chem 2022; 70: 11967-11980.","journal-title":"J Agric Food Chem"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1016\/S0140-6736(21)00880-1","article-title":"Long-term effects of COVID-19 on kidney function","volume":"397","author":"Enghard","year":"2021","unstructured":"Enghard P, Hardenberg JH, Stockmann H, Hinze C, Eckardt KU and Schmidt-Ott KM. Long-term effects of COVID-19 on kidney function. Lancet 2021; 397: 1806-1807.","journal-title":"Lancet"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1080\/21655979.2021.2020394","article-title":"Compatibility of achyranthes bidentata components in reducing inflammatory response through arachidonic acid pathway for treatment of osteoarthritis","volume":"13","author":"Li","year":"2022","unstructured":"Li Z, Ma D, Peng L, Li Y, Liao Z and Yu T. Compatibility of achyranthes bidentata components in reducing inflammatory response through arachidonic acid pathway for treatment of osteoarthritis. Bioengineered 2022; 13: 1746-1757.","journal-title":"Bioengineered"},{"key":"ref49","unstructured":"Min F, Ziming J, Ming W, Bolin F, Xiaoqiao T, Wenhua C and Fanzhong S. Effectiveness of Fuling () and its extracts against spleen deficiency in rats tonifying spleen. J Tradit Chin Med 2023; 43: 501-506."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1039\/D0FO03143G","article-title":"Plantaginis Semen polysaccharides ameliorate renal damage through regulating NLRP3 inflammasome in gouty nephropathy rats","volume":"12","author":"Zhao","year":"2021","unstructured":"Zhao H, Xu J, Wang R, Tang W, Kong L, Wang W, Wang L, Zhang Y and Ma W. Plantaginis Semen polysaccharides ameliorate renal damage through regulating NLRP3 inflammasome in gouty nephropathy rats. Food Funct 2021; 12: 2543-2553.","journal-title":"Food Funct"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.2147\/DDDT.S414752","article-title":"Review of the protective mechanism of paeonol on cardiovascular disease","volume":"17","author":"Yang","year":"2023","unstructured":"Yang C, Cheng J, Zhu Q, Pan Q, Ji K and Li J. Review of the protective mechanism of paeonol on cardiovascular disease. Drug Des Devel Ther 2023; 17: 2193-2208.","journal-title":"Drug Des Devel Ther"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"24081","DOI":"10.1097\/MD.0000000000024081","article-title":"Traditional Chinese medicine on treating splenomegaly due to portal hypertension in cirrhosis: a protocol for systematic review and meta-analysis","volume":"100","author":"Wang","year":"2021","unstructured":"Wang Z, Chen Z, Fan Z and Jiang Y. Traditional Chinese medicine on treating splenomegaly due to portal hypertension in cirrhosis: a protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021; 100: 24081.","journal-title":"Medicine (Baltimore)"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"114366","DOI":"10.1016\/j.envres.2022.114366","article-title":"Panax notoginseng powder -assisted preparation of carbon-quantum-dots\/BiOCl with enriched oxygen vacancies and boosted photocatalytic performance","volume":"215","author":"Liao","year":"2022","unstructured":"Liao H, Ran Y, Zhong J, Li J, Li M and Yang H. Panax notoginseng powder -assisted preparation of carbon-quantum-dots\/BiOCl with enriched oxygen vacancies and boosted photocatalytic performance. Environ Res 2022; 215: 114366.","journal-title":"Environ Res"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/s41598-020-80523-7","article-title":"Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B","volume":"11","author":"Chang","year":"2021","unstructured":"Chang TS, Yang YH, Chen WM, Shen CH, Tung SY, Yen CW, Hsieh YY, Lee CP, Tsai ML, Hung CH and Lu SN. Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B. Sci Rep 2021; 11: 1365.","journal-title":"Sci Rep"},{"key":"ref55","unstructured":"Wenlin C, Fang L, Yuncheng Z, Jinzhen LV and Daguo Y. Effects of Zhenggan Huayu decoction combined with entecavir on gut microbiota in patients with chronic hepatitis B fibrosis. J Tradit Chin Med 2023; 43: 559-567."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s40121-022-00695-9","article-title":"Bacterial infections confer a risk of progression to acute-on-chronic liver failure in patients with HBV-related compensated cirrhosis during severe hepatitis flares","volume":"11","author":"Chu","year":"2022","unstructured":"Chu J, Yang Y, Liu Y, Pei L, Zhou Y, Lu T, Zhang Y, Hu H, Li Y, Yang F and Lin S. Bacterial infections confer a risk of progression to acute-on-chronic liver failure in patients with HBV-related compensated cirrhosis during severe hepatitis flares. Infect Dis Ther 2022; 11: 1839-1851.","journal-title":"Infect Dis Ther"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"277","DOI":"10.14218\/JCTH.2020.00004","article-title":"Histological outcome of Fuzheng Huayu plus entecavir combination therapy in chronic hepatitis B patients with significant liver fibrosis","volume":"8","author":"Gui","year":"2020","unstructured":"Gui HL, Zhao CQ, Wang Y, Gu HT, Wang WJ, Cai W, Guo Q, Bao SS, Xu LM and Xie Q. Histological outcome of Fuzheng Huayu plus entecavir combination therapy in chronic hepatitis B patients with significant liver fibrosis. J Clin Transl Hepatol 2020; 8: 277-284.","journal-title":"J Clin Transl Hepatol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1111\/jgh.15512","article-title":"Gut-liver-axis: barrier function of liver sinusoidal endothelial cell","volume":"36","author":"Wang","year":"2021","unstructured":"Wang Y and Liu Y. Gut-liver-axis: barrier function of liver sinusoidal endothelial cell. J Gastroenterol Hepatol 2021; 36: 2706-2714.","journal-title":"J Gastroenterol Hepatol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41575-022-00724-5","article-title":"The scientific basis of combination therapy for chronic hepatitis B functional cure","volume":"20","author":"Lim","year":"2023","unstructured":"Lim SG, Baumert TF, Boni C, Gane E, Levrero M, Lok AS, Maini MK, Terrault NA and Zoulim F. The scientific basis of combination therapy for chronic hepatitis B functional cure. Nat Rev Gastroenterol Hepatol 2023; 20: 238-253.","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/8\/ajtr0156562.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:55:11Z","timestamp":1766022911000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/8\/ajtr0156562.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":60,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/qdxj3369","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}